logo
Plus   Neg
Share
Email

Myriad, AstraZeneca Expand Collaboration To Include MyChoice HRD Plus Diagnostic

Myriad Genetics, Inc. (MYGN) announced that AstraZeneca will use the company's myChoice HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab). Myriad will use its myChoice HRD Plus test to evaluate patients enrolled in an ongoing Phase III trial. Under the collaboration, the companies will use the myChoice HRD Plus test to identify cases with homologous recombination deficiencies.

Myriad's myChoice HRD Plus is a homologous recombination deficiency test to detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Back-to-school and college spending is projected to exceed the $100 billion mark for the first time ever ever despite the coronavirus pandemic, according to an annual survey by the National Retail Federation or NRF. The survey released by NRF and Prosper Insights & Analytics projects total spending for K-12 and college combined to reach $101.6 billion in 2020, up from last year's $80.7 billion. U.S. laboratory equipment maker Thermo Fisher Scientific Inc. (TMO) and Netherlands-based Qiagen N.V. (QGEN) announced Thursday that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of Qiagen. The... Morgan Stanley (MS) reported better-than-expected Q2 results, bolstered by strong trading revenues, amid the COVID-19 pandemic.
Follow RTT